Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

Ascierto PA, Caracò C, Gershenwald JE, Hamid O, Ross M, Sullivan RJ, Puzanov I.

J Transl Med. 2018 Apr 17;16(1):101. doi: 10.1186/s12967-018-1477-8.

2.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 Apr 12. pii: e8446. doi: 10.15252/emmm.201708446. [Epub ahead of print]

3.

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Mendzelevski B, Ferber G, Janku F, Li BT, Sullivan RJ, Welsch D, Chi W, Jackson J, Weng O, Sager PT.

Cancer Chemother Pharmacol. 2018 Mar 30. doi: 10.1007/s00280-018-3564-1. [Epub ahead of print]

PMID:
29603015
4.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG.

J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.

PMID:
29567210
5.

Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124].

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Giacomo AD, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Apr;93:158. doi: 10.1016/j.ejca.2018.02.001. Epub 2018 Mar 13. No abstract available.

PMID:
29548533
6.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT.

JCI Insight. 2018 Feb 22;3(4). pii: 92352. doi: 10.1172/jci.insight.92352. [Epub ahead of print]

7.

The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.

Rahman R, Cortes A, Niemierko A, Oh KS, Flaherty KT, Lawrence DP, Sullivan RJ, Shih HA.

J Neurooncol. 2018 Feb 16. doi: 10.1007/s11060-018-2795-7. [Epub ahead of print]

PMID:
29453679
8.

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.

Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2467-2472. doi: 10.1073/pnas.1719264115. Epub 2018 Feb 16.

9.

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S.

Thyroid. 2018 Mar;28(3):328-339. doi: 10.1089/thy.2017.0322. Epub 2018 Feb 27.

PMID:
29378474
10.

Keeping Expectations in Check With Immune Checkpoint Inhibitors.

Temel JS, Gainor JF, Sullivan RJ, Greer JA.

J Clin Oncol. 2018 Jan 25:JCO2017762146. doi: 10.1200/JCO.2017.76.2146. [Epub ahead of print] No abstract available.

PMID:
29369730
11.

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Mar;91:116-124. doi: 10.1016/j.ejca.2017.12.007. Epub 2018 Jan 19. Erratum in: Eur J Cancer. 2018 Mar 13;:.

12.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

PMID:
29247021
13.

A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.

Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H.

Cancer Immunol Res. 2018 Jan;6(1):79-86. doi: 10.1158/2326-6066.CIR-17-0412. Epub 2017 Dec 5.

PMID:
29208646
14.

Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.

Wang GX, Kurra V, Gainor JF, Sullivan RJ, Flaherty KT, Lee SI, Fintelmann FJ.

Radiographics. 2017 Nov-Dec;37(7):2132-2144. doi: 10.1148/rg.2017170085. Review.

PMID:
29131763
15.

The Mars Science Laboratory (MSL) Mast cameras and Descent imager: Investigation and instrument descriptions.

Malin MC, Ravine MA, Caplinger MA, Tony Ghaemi F, Schaffner JA, Maki JN, Bell JF 3rd, Cameron JF, Dietrich WE, Edgett KS, Edwards LJ, Garvin JB, Hallet B, Herkenhoff KE, Heydari E, Kah LC, Lemmon MT, Minitti ME, Olson TS, Parker TJ, Rowland SK, Schieber J, Sletten R, Sullivan RJ, Sumner DY, Aileen Yingst R, Duston BM, McNair S, Jensen EH.

Earth Space Sci. 2017 Aug;4(8):506-539. doi: 10.1002/2016EA000252. Epub 2017 Aug 19.

16.

Resistance to checkpoint blockade therapy through inactivation of antigen presentation.

Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, Yizhak K, Ray JP, Rosebrock D, Livitz D, Adalsteinsson V, Getz G, Duncan LM, Li B, Corcoran RB, Lawrence DP, Stemmer-Rachamimov A, Boland GM, Landau DA, Flaherty KT, Sullivan RJ, Hacohen N.

Nat Commun. 2017 Oct 26;8(1):1136. doi: 10.1038/s41467-017-01062-w.

17.

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.

Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.

Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27.

18.

The evolutionary nature of the cancer immunotherapy revolution.

Sullivan RJ.

Future Oncol. 2017 Aug;13(18):1565-1567. doi: 10.2217/fon-2017-0232. Epub 2017 Aug 22. No abstract available.

19.

Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.

Mooradian MJ, Sullivan RJ.

Future Oncol. 2017 Aug;13(18):1649-1663. doi: 10.2217/fon-2017-0117. Epub 2017 Aug 4.

PMID:
28776423
20.

Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.

Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, Flaherty KT, Lawrence DP, Johnson DB, Sullivan RJ.

Oncologist. 2017 Aug;22(8):963-971. doi: 10.1634/theoncologist.2016-0450. Epub 2017 May 5.

PMID:
28476944
21.

Immune checkpoint inhibitors in challenging populations.

Johnson DB, Sullivan RJ, Menzies AM.

Cancer. 2017 Jun 1;123(11):1904-1911. doi: 10.1002/cncr.30642. Epub 2017 Feb 27. Review.

PMID:
28241095
22.

A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

Dagogo-Jack I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, Lawrence DP, Shaw AT, Sullivan RJ.

J Immunother. 2017 Apr;40(3):108-113. doi: 10.1097/CJI.0000000000000159.

PMID:
28221189
23.

Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood.

Gee MS, Ghazani AA, Haq R, Wargo JA, Sebas M, Sullivan RJ, Lee H, Weissleder R.

Nanomedicine. 2017 Apr;13(3):821-828. doi: 10.1016/j.nano.2016.12.006. Epub 2016 Dec 18.

24.

Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.

Miller MA, Sullivan RJ, Lauffenburger DA.

Clin Cancer Res. 2017 Feb 1;23(3):623-629. doi: 10.1158/1078-0432.CCR-16-0869. Epub 2016 Nov 28. Review.

25.

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.

Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ.

J Immunother. 2017 Jan;40(1):31-35.

PMID:
27846054
26.

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM.

Cancer Immunol Res. 2016 Nov;4(11):959-967. Epub 2016 Sep 26.

27.

The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA.

Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17.

28.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ.

Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.

29.

Inherent vs Apparent Chemoselectivity in the Kumada-Corriu Cross-Coupling Reaction.

Hua X, Masson-Makdissi J, Sullivan RJ, Newman SG.

Org Lett. 2016 Oct 4. [Epub ahead of print]

PMID:
27696884
30.

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.

Ann Oncol. 2017 Feb 1;28(2):368-376. doi: 10.1093/annonc/mdw443.

PMID:
27687304
31.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

32.

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.

Shen CH, Kim SH, Trousil S, Frederick DT, Piris A, Yuan P, Cai L, Gu L, Li M, Lee JH, Mitra D, Fisher DE, Sullivan RJ, Flaherty KT, Zheng B.

Nat Med. 2016 Sep;22(9):1056-61. doi: 10.1038/nm.4155. Epub 2016 Aug 8.

33.

Melanoma driver mutations and immune therapy.

Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA.

Oncoimmunology. 2016 Mar 10;5(5):e1051299. doi: 10.1080/2162402X.2015.1051299. eCollection 2016 May.

34.

An EMS Guide to DEPRESSION AND BIPOLAR DISORDER.

Sullivan RJ, Sullivan S.

EMS World. 2016 Jun;45(6):48-56. No abstract available.

PMID:
27434992
35.

Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib Therapy.

Tseng D, Mason XL, Neilan TG, Sullivan RJ.

Oncologist. 2016 Sep;21(9):1136-7. doi: 10.1634/theoncologist.2016-0080. Epub 2016 Jul 7. No abstract available.

36.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS.

Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270.

37.

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M.

Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.

38.

The low prevalence of female smoking in the developing world: gender inequality or maternal adaptations for fetal protection?

Hagen EH, Garfield MJ, Sullivan RJ.

Evol Med Public Health. 2016 Jul 4;2016(1):195-211. doi: 10.1093/emph/eow013. Print 2016.

39.

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA.

Oncoimmunology. 2016 Feb 2;5(3):e1136044. eCollection 2016 Mar.

40.

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.

Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL Jr, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA.

JAMA Oncol. 2016 Aug 1;2(8):1056-64. doi: 10.1001/jamaoncol.2016.0509.

41.

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.

Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, Lu D, Genshaft AS, Hughes TK, Ziegler CG, Kazer SW, Gaillard A, Kolb KE, Villani AC, Johannessen CM, Andreev AY, Van Allen EM, Bertagnolli M, Sorger PK, Sullivan RJ, Flaherty KT, Frederick DT, Jané-Valbuena J, Yoon CH, Rozenblatt-Rosen O, Shalek AK, Regev A, Garraway LA.

Science. 2016 Apr 8;352(6282):189-96. doi: 10.1126/science.aad0501.

42.

Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF-mutant melanoma.

Sullivan RJ.

Br J Dermatol. 2016 Apr;174(4):716-7. doi: 10.1111/bjd.14503. No abstract available.

PMID:
27115584
43.

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance.

Miller MA, Oudin MJ, Sullivan RJ, Wang SJ, Meyer AS, Im H, Frederick DT, Tadros J, Griffith LG, Lee H, Weissleder R, Flaherty KT, Gertler FB, Lauffenburger DA.

Cancer Discov. 2016 Apr;6(4):382-99. doi: 10.1158/2159-8290.CD-15-0933. Epub 2016 Mar 16.

44.

The role of mitogen-activated protein targeting in melanoma beyond BRAFV600.

Sullivan RJ.

Curr Opin Oncol. 2016 Mar;28(2):185-91. doi: 10.1097/CCO.0000000000000271. Review.

PMID:
26844986
45.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM.

Nat Commun. 2016 Jan 29;7:10582. doi: 10.1038/ncomms10582.

46.

Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort.

Sanchez A, Rodríguez D, Allard CB, Bechis SK, Sullivan RJ, Boeke CE, Kuppermann D, Cheng JS, Barrisford GW, Preston MA, Feldman AS.

Urol Oncol. 2016 Apr;34(4):166.e7-14. doi: 10.1016/j.urolonc.2015.11.009. Epub 2015 Dec 28.

PMID:
26739672
47.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.

JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.

PMID:
26633184
48.

Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.

Lubitz CC, Parangi S, Holm TM, Bernasconi MJ, Schalck AP, Suh H, Economopoulos KP, Gunda V, Donovan SE, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ.

J Mol Diagn. 2016 Jan;18(1):100-8. doi: 10.1016/j.jmoldx.2015.08.003. Epub 2015 Nov 26.

49.

The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.

Akabane H, Sullivan RJ.

Am J Clin Dermatol. 2016 Feb;17(1):1-10. doi: 10.1007/s40257-015-0159-z. Review.

PMID:
26518880
50.

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.

Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, Sullivan RJ, Frederick DT, Abedalthagafi M, Jones PS, Dunn IF, Nahed BV, Romero JM, Louis DN, Getz G, Cahill DP, Santagata S, Curry WT Jr, Barker FG 2nd.

J Natl Cancer Inst. 2015 Oct 23;108(2). pii: djv310. doi: 10.1093/jnci/djv310. Print 2016 Feb.

Supplemental Content

Loading ...
Support Center